Cargando…

Outcomes of Gleason Score ≤8 among High Risk Prostate Cancer Treated with (125)I Low Dose Rate Brachytherapy Based Multimodal Therapy

PURPOSE: To investigate the role of low dose rate (LDR) brachytherapy-based multimodal therapy in high-risk prostate cancer (PCa) and analyze its optimal indications. MATERIALS AND METHODS: We reviewed the records of 50 high-risk PCa patients [clinical stage ≥T2c, prostate-specific antigen (PSA) >...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Dong Soo, Gong, In Hyuck, Choi, Don Kyung, Hwang, Jin Ho, Shin, Hyun Soo, Oh, Jong Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Yonsei University College of Medicine 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743192/ https://www.ncbi.nlm.nih.gov/pubmed/23918571 http://dx.doi.org/10.3349/ymj.2013.54.5.1207

Ejemplares similares

Impact of Gleason Pattern 5 on outcomes of patients with prostate cancer and iodine-125 prostate brachytherapy
por: Makino, Tomoyuki, et al.
Publicado: (2016)

Favorable intermediate risk prostate cancer with biopsy Gleason score of 6
por: Oh, Jong Jin, et al.
Publicado: (2021)

ARRDC4 and UBXN1: Novel Target Genes Correlated with Prostate Cancer Gleason Score
por: Oh, Jong Jin, et al.
Publicado: (2021)

Multimodal Radiomic Features for the Predicting Gleason Score of Prostate Cancer
por: Chaddad, Ahmad, et al.
Publicado: (2018)

Role of prostate health index to predict Gleason score upgrading and high-risk prostate cancer in radical prostatectomy specimens
por: Kim, Hwanik, et al.
Publicado: (2021)

Biochemical Recurrence in Gleason Score 7 Prostate Cancer in Korean Men: Significance of the Primary Gleason Grade
por: Ro, Yun Kwan, et al.
Publicado: (2012)

New sparse implantation technique of I-125 low-dose-rate brachytherapy using concomitant short-term hormonal treatment for low and intermediate-risk prostate cancer: An initial study of therapeutic feasibility
por: Yu, Young Dong, et al.
Publicado: (2019)

Predictive Factors and Oncologic Outcome of Downgrade to Pathologic Gleason Score 6–7 after Radical Prostatectomy in Patients with Biopsy Gleason Score 8–10
por: Chung, Doo Yong, et al.
Publicado: (2019)

Conventional dose versus dose escalated radiotherapy including high-dose-rate brachytherapy boost for patients with Gleason score 9–10 clinical localized prostate cancer
por: Yamazaki, Hideya, et al.
Publicado: (2022)

The Use of Exome Genotyping to Predict Pathological Gleason Score Upgrade after Radical Prostatectomy in Low-Risk Prostate Cancer Patients
por: Oh, Jong Jin, et al.
Publicado: (2014)

Analysis of monotherapy prostate brachytherapy in patients with prostate cancer. Initial PSA and Gleason are important for recurrence?
por: Galego, Pedro, et al.
Publicado: (2015)

pT3 Predictive Factors in Patients with a Gleason Score of 6 in Prostate Biopsies
por: Kim, Sung Jin, et al.
Publicado: (2011)

CRMP4 CpG Hypermethylation Predicts Upgrading to Gleason Score ≥ 8 in Prostate Cancer
por: Qin, Xiao-Ping, et al.
Publicado: (2022)

Validation of the WHO 2016 new Gleason score of prostatic carcinoma
por: Rao, Vishal, et al.
Publicado: (2018)

Beyond the Gleason score: the prognostic significance of prostate cancer subtypes
por: Flood, Trevor A., et al.
Publicado: (2018)

Expression of stromal elements of prostatic adenocarcinoma in different gleason scores
por: Osorio, Clarice Fraga Esteves Maciel, et al.
Publicado: (2019)

The Ability of Prostate Health Index (PHI) to Predict Gleason Score in Patients With Prostate Cancer and Discriminate Patients Between Gleason Score 6 and Gleason Score Higher Than 6—A Study on 320 Patients After Radical Prostatectomy
por: Dolejsova, Olga, et al.
Publicado: (2018)

Predictive Factors of Gleason Score Upgrading in Localized and Locally Advanced Prostate Cancer Diagnosed by Prostate Biopsy
por: Moon, Seung Jin, et al.
Publicado: (2010)

Cribriform architecture in radical prostatectomies predicts oncological outcome in Gleason score 8 prostate cancer patients
por: Hollemans, Eva, et al.
Publicado: (2020)

The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score ≥ 7 prostate cancer from group of biopsy-based Gleason score ≤ 6
por: Wang, Hanfeng, et al.
Publicado: (2017)

Prognostic Models for Patients With Gleason Score 9 Prostate Cancer: A Population-Based Study
por: Qiu, Jianhui, et al.
Publicado: (2021)

Difference in the rate of rectal complications following prostate brachytherapy based on the prostate-rectum distance and the prostate longitudinal length among early prostate cancer patients
por: Kang, Moon Hyung, et al.
Publicado: (2015)

Differences in survival of prostate cancer Gleason 8–10 disease and the establishment of a new Gleason survival grading system
por: Zhou, Yuan, et al.
Publicado: (2020)

Correlation of Gleason Scores with Diffusion-Weighted Imaging Findings of Prostate Cancer
por: Nagarajan, Rajakumar, et al.
Publicado: (2012)

Predicting Gleason Score of Prostate Cancer Patients Using Radiomic Analysis
por: Chaddad, Ahmad, et al.
Publicado: (2018)

MYC DNA Methylation in Prostate Tumor Tissue is Associated with Gleason Score
por: Barry, Kathryn Hughes, et al.
Publicado: (2020)

Ten‐step method of high‐dose LDR (125)I brachytherapy for intermediate‐risk prostate cancer
por: Okamoto, Keisei
Publicado: (2021)

Salvage low-dose-rate (125)I partial prostate brachytherapy after dose-escalated external beam radiotherapy
por: Chang, Lynn, et al.
Publicado: (2014)

Clinical Significance of a Large Difference (≥ 2 points) between Biopsy and Post-prostatectomy Pathological Gleason Scores in Patients with Prostate Cancer
por: Yoo, Changhee, et al.
Publicado: (2011)

Correlation between Gleason score distribution and Prostate Health Index in patients with prostate-specific antigen values of 2.5–10 ng/mL
por: Choi, Joongwon, et al.
Publicado: (2020)

Can Contemporary Patients with Biopsy Gleason Score 3+4 Be Eligible for Active Surveillance?
por: Kwon, Ohseong, et al.
Publicado: (2014)

Prediction of pathologic upgrading in Gleason score 3+4 prostate cancer: Who is a candidate for active surveillance?
por: Pham, Duc Minh, et al.
Publicado: (2020)

Overall and worst gleason scores are equally good predictors of prostate cancer progression
por: Tolonen, Teemu T, et al.
Publicado: (2011)

AB177. Clinical and pathological research of prostate cancer with Gleason score 10
por: Yan, Bin, et al.
Publicado: (2016)

Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy
por: Geybels, Milan S., et al.
Publicado: (2016)

Phospholipase D2 in prostate cancer: protein expression changes with Gleason score
por: Noble, Amanda R., et al.
Publicado: (2019)

Validation of an MRI-based prostate cancer prebiopsy Gleason score predictive nomogram
por: Lee, Adrianna Jiaying, et al.
Publicado: (2022)

Erectile function after permanent 125I prostate brachytherapy for localized prostate cancer
por: Njomnang Soh, Patrice, et al.
Publicado: (2013)

Aberrant Promoter Methylation of Protocadherin8 (PCDH8) in Serum is a Potential Prognostic Marker for Low Gleason Score Prostate Cancer
por: Lin, Ying-Li, et al.
Publicado: (2017)

Prostate Cancer in Patients with Metabolic Syndrome Is Associated with Low Grade Gleason Score When Diagnosed on Biopsy
por: Jeon, Kyoung Pil, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_rudp3l248i8ucasbn9ip9kqlog